Abstract
ObjectiveTo investigate the risk factors and drug resistance of MDR Acinetobacter baumannii in pneumonia patients.MethodsFrom January 2013 to February 2016, 98 pneumonia patients with MDR Acinetobacter baumannii in our hospital ICU were selected as the observation group, and 49 pneumonia patients with not-MDR Acinetobacter baumannii in our hospital ICU were selected as the control group in accordance with the proportion of 2:1. Sputum samples were collected from the two groups for drug resistance, and the risk factors and prognosis of MDR Acinetobacter baumannii in pneumonia patients were given survey analysis.ResultsThe observation group was highly resistant to cefotaxime, piperacillin, imipenem, levofloxacin, gentamicin, tetracycline and ceftazidime, and was only sensitive to polymyxin. In addition to piperacillin, polymyxin B, the other antimicrobial drug resistance rates in the control group was significantly lower than in the observation group (P<0.05). Univariate analysis showed that diabetes, infection before hospitalization, admission 24h score of APACHE II and GCS scores, deep venous catheterization, and mechanical ventilation were related to the MDR Acinetobacter baumannii in pneumonia patients(P<0.05). Non conditional logistic regression analysis showed that diabetes mellitus, infection before hospitalization, admission 24h score of APACHE II and GCS scores were the independent risk factors for the MDR Acinetobacter baumannii in pneumonia patients(P<0.05).ConclusionMDR Acinetobacter baumannii in pneumonia patients in ICU is common, where diabetes infection before hospitalization, admission 24h score of APACHE II and GCS scores are the main risk factors, and the vast majority of the antibiotics are resistant to the MDR Acinetobacter baumannii that can lead to poorer prognosis and followed-up of patients with increased mortality.
Highlights
Acinetobacter baumannii belongs to the genus of acreasia, is a gram-negative non-fermenting bacteria, in which only one or two antimicrobial agents are sensitive to Acinetobacter baumannii called pan resistant to Acinetobacter baumannii [1]
It has been found that the incidence rate of ICU pan-resistant Acinetobacter baumannii pneumonia is increasing year by year, and how to effectively control pneumonia caused by ICU-resist
Accepting criteria: 98 patients as an observation group was selected to stay in our hospital ICU ward after diagnosis of pan-resistant Acinetobacter baumannii pneumonia in January 2013 to February 2016, which is in line with hospital diagnostic criteria for pneumonia; lower respiratory tract secretions bacteria was checked for the pan-resistant Acinetobacter baumannii; excluding admission and ICU time less than 48h patients
Summary
Acinetobacter baumannii belongs to the genus of acreasia, is a gram-negative non-fermenting bacteria, in which only one or two antimicrobial agents are sensitive to Acinetobacter baumannii called pan resistant to Acinetobacter baumannii [1]. Pan-resistant Acinetobacter baumannii is widely distributed in water, dirt, soil and hospital environment. Studies have revealed that pan-resistant Acinetobacter baumannii infection has obvious characteristics of the distribution of departments, including intensive care unit (Intensive Care Unit, ICU) infection rate near the top [4,5]. It has been found that the incidence rate of ICU pan-resistant Acinetobacter baumannii pneumonia is increasing year by year, and how to effectively control pneumonia caused by ICU-resist-. Risk factors and drug resistance of the MDR Acinetobacter baumannii in pneumonia patients in ICU 773 ant Acinetobacter baumannii and reduce its incidence has attracted wide spread attention [8,9]. We investigated the risk factors of acetobacter baumannii in patients with ICU pneumonia and analyzed the drug resistance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
